Last reviewed · How we verify
Huperzine A Controlled-Release Tablets
Huperzine A is a reversible cholinesterase inhibitor that increases acetylcholine levels in the brain.
Huperzine A is a reversible cholinesterase inhibitor that increases acetylcholine levels in the brain. Used for Alzheimer's disease.
At a glance
| Generic name | Huperzine A Controlled-Release Tablets |
|---|---|
| Sponsor | Wanbangde Pharmaceutical Group Co., LTD |
| Drug class | Cholinesterase inhibitor |
| Target | Acetylcholinesterase |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 2 |
Mechanism of action
By inhibiting acetylcholinesterase, Huperzine A prevents the breakdown of acetylcholine, a neurotransmitter involved in memory and cognitive function. This leads to increased acetylcholine levels, which can improve memory and cognitive performance. Huperzine A's mechanism is similar to that of donepezil, a commonly used Alzheimer's medication.
Approved indications
- Alzheimer's disease
Common side effects
- Nausea
- Diarrhea
- Vomiting
- Headache
- Fatigue
Key clinical trials
- Clinical Study to Evaluate the Efficacy and Safety of Huperzine A Controlled-Release Tablets in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type (PHASE2, PHASE3)
- Study of Huperzine A Sustained-Release Tablets in Patients With Alzheimer's Disease (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: